Article
Version 1
Preserved in Portico This version is not peer-reviewed
Safety and Efficacy of Autologous Stem Cell Treatment for Facetogenic Chronic Back Pain
Version 1
: Received: 30 January 2023 / Approved: 1 February 2023 / Online: 1 February 2023 (04:40:12 CET)
A peer-reviewed article of this Preprint also exists.
Rothoerl, R.; Tomelden, J.; Alt, E.U. Safety and Efficacy of Autologous Stem Cell Treatment for Facetogenic Chronic Back Pain. J. Pers. Med. 2023, 13, 436. Rothoerl, R.; Tomelden, J.; Alt, E.U. Safety and Efficacy of Autologous Stem Cell Treatment for Facetogenic Chronic Back Pain. J. Pers. Med. 2023, 13, 436.
Abstract
Background: Chronic Back Pain due to Facet Joint Syndrome is a common and debilitating con-dition. Advances in regenerative medicine have shown that Autologous Unmodified Adipose Tissue-Derived Regenerative Cells (ADRC) provide several beneficial effects [1,2]. These regen-erative cells can differentiate into various tissues [3] and exhibit a strong anti-inflammatory po-tential. ADRCs can be obtained from a small amount of fatty tissue derived from the patient´s abdominal fat. Methods: We report long-term results of 37 patients (age 31-78 years, mean 62.5) suffering from “Facet Joint Syndrome” The pathology was confirmed by clinical, radiological examinations and fluoroscopically guided test injections. Then liposuction was performed. 50-100 cc of fat were harvested. To recover stem cells from adipose tissue, we use the CE-certified Transpose RT™ system from InGeneron GmbH. The cells were then injected under fluoroscopic control in the periarticular fat. Follow-up examinations were performed at one week 1 and 5 years. Results: Every patient reported improved VAS pain at any follow-up (1 week, 1, and 5 years) with ADRCs compared to the baseline. Conclusion: Our observational data indicate that facet joint syndrome patients treated with unmodified adipose tissue-derived regenerative cells experience improved quality of life in the long term.
Keywords
Facet joint syndrome; adipose tissue-derived regenerative cells
Subject
Medicine and Pharmacology, Anesthesiology and Pain Medicine
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment